STOCKHOLM – February 11, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that an agreement to conduct clinical evaluations of ContextVision’s digital pathology product INIFY® Prostate Screening has been signed with Vall d’Hebron University Hospital in Barcelona, Spain.
“Digitalization opens up for using advanced AI tools to facilitate the pathologists’ work. This is highly appreciated as the workload just keeps on accelerating. We are going to test INIFY Prostate Screening program at our hospital to learn how it could improve patient care and workflow,” says Dra. Ines de Torres, chief of Uropathology Unit at Vall d’Hebron University Hospital.
Vall d’Hebron University Hospital processes around 20–30 prostate biopsy cases per week and is a reference site for the region. The eight public hospitals in the Catalonia region are presently involved in a digitalization process of their pathology departments.
INIFY® Prostate Screening is a powerful AI-based software that predicts, outlines and quantifies suspicious cancerous areas in a series of prostate biopsies. The predictions are performed prior to the pathologists opening the worklist, and cases and slides within the case are pre-sorted in a worst-first order, allowing pathologists to get right to work on the most relevant areas.
“We really look forward to working together with the pathology department at Vall d’Hebron, as part of our determination to drive digitalization by offering powerful decision support tools”, says Magnus Aurell, VP Business Unit Digital Pathology at ContextVision.
For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43 or visit www.contextvision.com.
About ContextVision
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world.
Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
ContextVision is now entering the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.
The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.
Attachment